The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall ...

Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...

Rosenblatt Securities reissued their buy rating on shares of Dolby Laboratories (NYSE:DLB – Free Report) in a report issued on Thursday,Benzinga reports. The brokerage currently has a $100.00 price ...

S&P 500 E-Mini futures (ESH25) are down -0.15%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.27% this morning as market participants braced for the Federal Reserve’s interest rate decision ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...